


FOR METASTATIC BREAST CANCER (MBC) HEALTH CARE PROFESSIONALS

Providing care for individuals with MBC presents a dilemma. Most will remain on therapy indefinitely, and treatment is often disrupted by drug toxicities that impact therapeutic efficacy and quality of life.



Toxicity Is a Significant Issue


Based on a survey¹ of 1,221 patients with MBC:



20% visited the ER/hospital



43% missed scheduled treatment



83% of patients felt better upon receiving dose reduction for side effect palliation

“More Is Better” Is No Longer the Standard

The FDA’s Project Optimus states, “Sponsors should carefully evaluate exposure-response, efficacy, and safety data from early trials to inform dose selection, rather than automatically selecting the maximum tolerated dose.”²

Talk With Patients to Identify an Optimal Dose Together



To jointly determine the most favorable dose **upon treatment initiation and thereafter**, health care professionals and their patients should consider:

- The patient’s personal goals and wishes
- Performance status
- History of side effects from other drugs
- Current and past blood counts
- Indolent vs. aggressive disease
- Organ dysfunction/CNS metastases
- Body Mass Index
- Ability to afford medication or specialist visits to ease side effects
- Availability of patients’ at-home care

Investigate Options for Mitigating Side Effects




Some strategies to discuss with patients may include:

- Dosage reduction
- Altering treatment frequency
- Palliative medications
- Switching treatments
- Referral to specialist
- Changing drug manufacturers
- Complementary measures (e.g. acupuncture, yoga)

Ask Patients About Side Effects at Every Visit!



Though **100%** of surveyed medical oncologists³ said they inquire about patients’ side effects at every visit, only **77%** of surveyed MBC patients said this was the case.



10% of surveyed MBC patients reported that they were rarely – or never – asked about their treatment-related side effects.



Questions/Comments: Visit the Patient-Centered Dosing Initiative at TheRightDose.org or email info@TheRightDose.org

1 Loeser AL, Peppercorn JM, Burkard ME, et al: Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC). JCO 39:1005–1005, 2021
2 Shah M, et al: The Drug-Dosing Conundrum in Oncology — When Less Is More. N Engl J Med 10/2021; 385:1445-1447
3 Loeser AL, Gao L, Bardia A, et al: Patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast Cancer Res Treat 196:549–563, 2022



#TheRightDose